Crescent Grove Advisors LLC Acquires 13,048 Shares of NCR Atleos Corporation $NATL

Posted by Geri Gentry on Jul 19th, 2026

Crescent Grove Advisors LLC increased its holdings in NCR Atleos Corporation (NYSE:NATL – Free Report) by 3.4% in the first quarter, Holdings Channel.com reports. The firm owned 401,456 shares of the company’s stock after acquiring an additional 13,048 shares during the period. NCR Atleos makes up approximately 1.7% of Crescent Grove Advisors LLC’s investment portfolio, making the stock its 16th biggest position. Crescent Grove Advisors LLC’s holdings in NCR Atleos were worth $17,495,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Fourth Sail Capital LP purchased a new position in NCR Atleos in the 4th quarter worth $33,597,000. Simcoe Capital Management LLC purchased a new stake in NCR Atleos during the second quarter valued at about $20,282,000. Millennium Management LLC purchased a new stake in NCR Atleos during the third quarter valued at about $14,900,000. Pillsbury Lake Capital LLC bought a new position in shares of NCR Atleos during the fourth quarter valued at about $10,217,000. Finally, Capital International Investors grew its stake in shares of NCR Atleos by 63.0% during the fourth quarter. Capital International Investors now owns 682,561 shares of the company’s stock valued at $26,012,000 after buying an additional 263,698 shares during the last quarter. Institutional investors own 88.66% of the company’s stock.

NCR Atleos Trading Up 0.7%

NYSE:NATL opened at $47.43 on Friday. The firm has a market capitalization of $3.50 billion, a P/E ratio of 20.44 and a beta of 0.60. The company has a quick ratio of 0.78, a current ratio of 0.98 and a debt-to-equity ratio of 6.83. The company has a fifty day moving average of $44.53 and a 200 day moving average of $42.94. NCR Atleos Corporation has a 52 week low of $23.56 and a 52 week high of $48.50.

NCR Atleos (NYSE:NATL – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.89 by ($0.24). NCR Atleos had a return on equity of 78.64% and a net margin of 3.98%.The firm had revenue of $1.04 billion during the quarter. During the same quarter in the previous year, the business posted $0.64 earnings per share. The firm’s revenue was up 6.5% on a year-over-year basis. On average, research analysts predict that NCR Atleos Corporation will post 4.52 earnings per share for the current year.

Analysts Set New Price Targets

NATL has been the topic of several analyst reports. Zacks Research downgraded NCR Atleos from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 27th. Weiss Ratings cut NCR Atleos from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 8th. Finally, DA Davidson restated a “neutral” rating and set a $50.00 price target on shares of NCR Atleos in a research report on Monday, May 11th. Six research analysts have rated the stock with a Hold rating, According to data from MarketBeat, NCR Atleos currently has a consensus rating of “Hold” and an average target price of $50.27.

View Our Latest Research Report on NCR Atleos

NCR Atleos Company Profile

(Free Report)

NCR Atleos Corporation operates as a financial technology company in the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Self-Service Banking, Network, and Telecommunications & Technology (T&T). The Self-Service Banking segment offers solutions, including a line of automated teller machine (ATM) and interactive teller machine (ITM) hardware and software, as well as related installation, maintenance, and managed and professional services; and solutions to manage and run the ATM channel end-to-end for financial institutions comprising back office, cash management, software management and ATM deployment, and others.